Update on COVID-19 in Transplantation: from Travel to Treatment
On May 24, 2022, the Massachusetts General Hospital Transplant Center held a virtual, fireside chat to share the latest updates on COVID-19 and transplantation.
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
Call us to learn more, or request an appointment online.
Transcatheter aortic valve replacement (also known as TAVR or TAVI) is a minimally invasive procedure used by physicians at the Massachusetts General Hospital Corrigan Minhean Heart Center to treat patients with aortic valve stenosis.
Patients who have severe aortic stenosis (a narrowing of the valve that restricts blood flow) and are considered high risk or non-operable for open-heart surgery may be candidates for the transcatheter aortic valve replacement (also known as TAVR or TAVI) procedure.
During this procedure, physicians use minimally invasive techniques to implant a new heart valve without open-heart surgery. Physicians use a transfemoral (from the leg), transaxillary (from the shoulder), or transapical (through the chest) approach, by inserting a transcatheter heart valve that is mounted and crimped onto a balloon delivery catheter. It is then threaded through the patient’s circulatory system and directly into the heart’s pumping chamber.
Upon reaching the site of the patient’s diseased heart valve, the balloon expands, and the transcatheter heart valve is deployed across the patient’s diseased valve. This procedure is performed on a beating heart, meaning that there is no need for a cardiopulmonary bypass and its associated risks.
Transcatheter aortic valve replacement has been proven to have superior safety and efficacy and is currently approved by the US Food and Drug Administration for patients with aortic valve stenosis that are at high or extreme risk for open-heart surgery. Healthier patients may have an opportunity to receive transcatheter aortic valve replacement through one of our ongoing clinical studies.
Our multidisciplinary care team includes cardiac surgeons, interventional cardiologists, noninvasive cardiologists, cardiac anesthesiologists, cardiac imaging specialists, nurse practitioners, registered nurses and technicians with robust experience in the evaluation and treatment of patients with valvular heart disease. Patients referred to us undergo a thorough evaluation in order to determine the treatment option that would be best for the patient. Specifically, all patients being considered for TAVR will receive:
Mass General is the #1 Research Hospital in America and recognized in 14 specialties assessed by U.S. News & World Report.
Our physicians welcome second opinion appointments to review cases and proposed lines of treatment.
On May 24, 2022, the Massachusetts General Hospital Transplant Center held a virtual, fireside chat to share the latest updates on COVID-19 and transplantation.
Women who had experienced infertility had a 16% increased risk of heart failure compared with women who did not have an infertility history.
Advanced consumer technology has produced small electrocardiogram devices that could be efficiently deployed in point-of-care screening for atrial fibrillation, though the proportion of cases detected among all patients 65 and older is small.
Mutations in genes that direct the production of fibrillar collagens, essential components of blood vessel walls, appear to predispose individuals to SCAD.
Heart disease is the leading cause of death in men and women alike. In this presentation, Dr. Emily Lau reviews the epidemiology of heart disease in women, differences in heart disease between women and men, and special considerations for promoting female heart health.
“Thank you for your service” is a phrase shared with U.S. service members. But Mass General’s Shannon Stuart, RN, a commissioned officer with the Air National Guard, says she is the one who feels the need to share her appreciation.
Call us to learn more, or request an appointment online.